KCNK9 and breast cancer: Sun et al. developed monoclonal antibodies against the special KCNK9 extracellular domain by leveraging the domain’s poor sensitivity to common ion channel blockage and proved that they could inhibit lung and breast cancer cell growth in vivo [32].